[Effects of attenuated measles virus on hepatitis B virus in vivo and in vitro].
OBJECTIVE
To observe the effects of attenuated measles virus on hepatitis B virus replication inside and outside the body.


METHODS
Patients with chronic hepatitis B virus replication were chosen, and attenuated measles viruses were inoculated in them and observed twice every week for a total of 48 weeks. The changes of CD4+, CD8+, IFN-gamma, IL-2, HBeAg and HBV DAN were observed. Also the changes of the HBVM were observed when adding the measles virus in suspension of the 2.2.15 cells.


RESULTS
The average ratio of CD4+ and CD8+ before the treatment was 1.05 +/- 0.19 and it rose to 1.47 +/- 0.18 after follow up for 48 weeks. Then, compared with the ratio before the treatment, the difference was significant(t = 5.36, P < 0.01). After inoculating the measles virus for two weeks, IFN-gamma and IL-2 increased. Although the total average ratio had not great difference, IL-2 level of 26.3% of the cases elevated 5 times higher in the second week, as compared with the control group, there was a great difference (chi 2 = 12.07, P < 0.005). The results of the examination of the HBeAg before treatment was 317, 35 +/- 151.75, but became 139.17 +/- 166.66 after observing for 48 weeks(t = 2.16, P < 0.05). The positive ratio of HBV DNA before the treatment was 100% and become 63.16% after treatment. Thus the ratio difference is significant(chi 2 = 10.08, P < 0.005). However, no such ratio difference was found in the control group. When adding the attenuated measles virus in suspension of 2.2.15 cell, the HBsAg and HBeAg decreased.


CONCLUSIONS
When the measles virus and hepatitis B virus infect the cases in an overlapping way, the latter may be interfered by change of the cell immunity status of the body of the former, and measles virus may have direct interference effects on hepatitis B virus.
Yang
Z
Z
Institute of Infectious disease, Guangzhou Municipal Infectious Disease Hospital, Guangzhou 510060, China.
Wu
W
W
Lu
Q
Q
D000328:Adult; D002478:Cells, Cultured; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000096:biosynthesis; D006513:Hepatitis B e Antigens / Q000096:biosynthesis; D006515:Hepatitis B virus / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000276:immunology* / Q000628:therapy; D006801:Humans; D008297:Male; D008458:Measles Vaccine / Q000494:pharmacology*; D014613:Vaccines, Attenuated / Q000494:pharmacology; D014762:Viral Interference; D014779:Virus Replication
D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D008458:Measles Vaccine; D014613:Vaccines, Attenuated